Gene therapy for Parkinson's disease: From non-human primates to humans

Current Opinion in Molecular Therapeutics

Volumn 12, Issue 5, 2010, Pages 519-529

  Fiandaca, Massimo S ^a   Bankiewicz, Krystof S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; AROMATIC LEVO AMINO ACID DECARBOXYLASE; DOXYCYCLINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMATE DECARBOXYLASE; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; LENTIVIRUS VECTOR; LEVODOPA; NEUROTROPHIC FACTOR; NEURTURIN; NLX P 101; PARVOVIRUS VECTOR; PLACEBO; TETRACYCLINE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONVECTIN ENHANCED DELIVERY; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; ENZYME PRODRUG THERAPY; ENZYME REPLACEMENT; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; PARKINSON DISEASE; PRIMATE; REVIEW; TRANSCRIPTION REGULATION; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; CLINICAL TRIALS AS TOPIC; GENE THERAPY; HUMANS; LENTIVIRUS; PARKINSON DISEASE; PRIMATES;

ADENO-ASSOCIATED VIRUS; LENTIVIRUS; PARKINSONIA; PRIMATES;

EID: 77957731467     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ: A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. Proc Natl Acad Sci USA (1983) 80 (14):4546-4550.
2. Bankiewicz KS, Oldfield EH, Chiueh CC, Doppman JL, Jacobowitz DM, Kopin IJ: Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP). Life Sci (1986) 39 (1):7-16. •• Definitive paper describing the hemiparkinsonian model in NHPs using intracarotid infusion of the MPTP neurotoxin.
3. Ungerstedt U: Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl (1971) 367:69-93.
4. Bankiewicz K, Mandel RJ, Sofroniew MV: Trophism, transplantation, and animal models of Parkinson's disease. Exp Neurol (1993) 124 (1):140-149.
5. Fiandaca MS, Gash DM: New insights and technologies in brain grafting. Clin Neurosurg (1992) 39:482-508.
6. Fiandaca MS, Kordower JH, Hansen JT, Jiao SS, Gash DM: Adrenal medullary autografts into the basal ganglia of cebus monkeys: Injury-induced regeneration. Exp Neurol (1988) 102 (1):76-91.
7. Plunkett RJ, Bankiewicz KS, Cummins AC, Miletich RS, Schwartz JP, Oldfield EH: Long-term evaluation of hemiparkinsonian monkeys after adrenal autografting or cavitation alone. J Neurosurg (1990) 73 (6):918-926.
8. B ankiewicz KS, Plunkett RJ, Jacobowitz DM, Kopin IJ, Oldfield EH: Fetal nondopaminergic neural implants in parkinsonian primates. Histochemical and behavioral studies. J Neurosurg (1991) 74 (1):97-104.
9. Bankiewicz KS, Palmatier M, Plunkett RJ, Cummins A, Oldfield EH: Reversal of hemiparkinsonian syndrome in nonhuman primates by amnion implantation into caudate nucleus. J Neurosurg (1994) 81 (6):869-876.
10. Bankiewicz KS, Leff SE, Nagy D, Jungles S, Rokovich J, Spratt K, Cohen L, Libonati M, Snyder RO, Mandel RJ: Practical aspects of the development of ex vivo and in vivo gene therapy for Parkinson's disease. Exp Neurol (1997) 144 (1):147-156.
11. Kaplitt MG, Leone P, Samulski RJ, Xiao X, Pfaff DW, O'Malley KL, During MJ: Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet (1994) 8 (2):148-154. (Pubitemid 24308362)
12. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH: Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA (1994) 91 (6):2076-2080. •• Definitive description of CED mechanisms for brain delivery.
13. Varenika V, Dickinson P, Bringas J, LeCouteur R, Higgins R, Park J, Fiandaca M, Berger M, Sampson J, Bankiewicz K: Detection of infusate leakage in the brain using real-time imaging of convection-enhanced delivery. J Neurosurg (2008) 109 (5):874-880.
14. Fiandaca MS, Varenika V, Eberling J, McKnight TR, Bringas J, Pivirotto P, Beyer J, Hadaczek P, Forsayeth J, Bowers WJ, Park J et al: Real-time MR imaging of adeno-associated viral vector delivery to the primate brain. Neuroimage (2009) 47 (Suppl 2): T27-T35.
15. Fiandaca MS, Forsayeth JR, Dickinson PJ, Bankiewicz KS: Image-guided convection-enhanced delivery platform in the treatment of neurological diseases. Neurotherapeutics (2008) 5 (1):123-127.
16. Samulski RJ, Berns KI, Tan M, Muzyczka N: Cloning of infectious adeno-associated virus into pBR322: Rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci USA (1982) 79 (6):2077-2081.
17. Heilbronn R, Weger S: Viral vectors for gene transfer: Current status of gene therapeutics. Handb Exp Pharmacol (2010) (197):143-170.
18. Sinn PL, Sauter SL, McCray PB Jr: Gene therapy progress and prospects: Development of improved lentiviral and retroviral vectors - Design, biosafety, and production. Gene Ther (2005) 12 (14) 1089-1098.
19. Fiandaca MS, Forsayeth J, Bankiewicz K: Current status of gene therapy trials for Parkinson's disease. Exp Neurol (2008) 209 (1):51-57.
20. Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, Bland RJ, Young D, Strybing K, Eidelberg D, During MJ: Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: An open label, phase I trial. Lancet (2007) 369 (9579):2097-2105. •• First report of successful clinical gene therapy for PD using the AAV2 vector and the GAD gene into the subthalamic nucleus.
21. Rezai AR, Machado AG, Deogoankar M, Azmi H, Kubu C, Boulis NM: Surgery for movement disorders. Neurosurgery (2008) 62 (Suppl 2):809-839.
22. Shimo Y, Wichmann T: Neuronal activity in the subthalamic nucleus modulates the release of dopamine in the monkey striatum. Eur J Neurosci (2009) 29 (1):104-113.
23. Eberling JL, Jagust WJ, Christine CW, Starr P, Larson P, Bankiewicz KS, Aminoff MJ: Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology (2008) 70 (21):1980-1983. •• First report of successful AADC enzyme replacement gene therapy into the putamen of patients with PD, with direct PET evidence of transgene function postoperatively.
24. Christine CW, Starr PA, Larson PS, Eberling JL, Jagust WJ, Hawkins RA, VanBrocklin HF, Wright JF, Bankiewicz KS, Aminoff MJ: Safety and tolerability of putaminal gene therapy for Parkinson's disease. Neurology (2009) 73 (20):1662-1669.
25. Marks WJ Jr, Ostrem JL, Verhagen L, Starr PA, Larson PS, Bakay RA, Taylor R, Cahn-Weiner DA, Stoessl AJ, Olanow CW, Bartus RT: Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: An open-label, phase I trial. Lancet Neurol (2008) 7 (5):400-408. •• Describes the well-tolerated implantation of AAV2-NTN neurotrophic factor gene therapy in patients with PD.
26. Kordower JH, Herzog CD, Dass B, Bakay RA, Stansell J 3rd, Gasmi M, Bartus RT: Delivery of neurturin by AAV2 (CERE-120) - mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol (2006) 60 (6):706-715.
27. Gasmi M, Brandon EP, Herzog CD, Wilson A, Bishop KM, Hofer EK, Cunningham JJ, Printz MA, Kordower JH, Bartus RT: AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: Long-term efficacy and tolerability of CERE-120 for Parkinson's disease. Neurobiol Dis (2007) 27 (1):67-76.
28. Neurologix Inc: Neurologix completes all surgical procedures in its clinical trial for Parkinson's disease. Press Release (2009): December 03. phx.corporate-ir.net/phoenix.zhtml?c=106413&p=irolnewsArticle & ID=1361608&highlight=
29. Neurologix Inc: Neurologix announces successful phase 2 trial of gene therapy for Parkinson's disease. Press release (2010): June 22. phx.corporate-ir.net/phoenix.zhtml?c=106413&p=irol-news Article & ID=1440622&highlight=
30. Valles F, Fiandaca MS, Eberling JL, Starr PA, Larson P, Christine CW, Forsayeth J, Richardson RM, Su X, Aminoff MJ, Bankiewicz KS: Imaging of AAV2-hAADC gene therapy infusion in a phase I study for the treatment of Parkinson's disease. Neurosurgery (2010): doi:10.1227/NEU.0b013e3181f53a5c.
31. Yin D, Valles FE, Fiandaca MS, Bringas J, Gimenez F, Berger MS, Forsayeth J, Bankiewicz KS: Optimal region of the putamen for image-guided convection-enhanced delivery of therapeutics in human and non-human primates. NeuroImage (2009): doi:10.1016/j.neuroimage.2009.08.069.
32. Allen GF, Land JM, Heales SJ: A new perspective on the treatment of aromatic L-amino acid decarboxylase deficiency. Mol Genet Metab (2009) 97 (1):6-14.
33. Manegold C, Hoffmann GF, Degen I, Ikonomidou H, Knust A, Laass MW, Pritsch M, Wilichowski E, Hörster F: Aromatic l-amino acid decarboxylase deficiency: Clinical features, drug therapy and follow-up. J Inherit Metab Dis (2009) 32 (3):371-380.
34. Jarraya B, Boulet S, Ralph GS, Jan C, Bonvento G, Azzouz M, Miskin JE, Shin M, Delzescaux T, Drouot X, Hérard AS et al: Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. Sci Transl Med (2009) 1 (2):2ra4.
35. Muramatsu S, Fujimoto K, Ikeguchi K, Shizuma N, Kawasaki K, Ono F, Shen Y, Wang L, Mizukami H, Kume A, Matsumura M et al: Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adenoassociated viral vectors expressing dopamine-synthesizing enzymes. Hum Gene Ther (2002) 13 (3):345-354.
36. Oxford Biomedica: Oxford BioMedica initiates phase I/II trial of ProSavin gene-based treatment for Parkinson's disease. Press Release (2007): December 13. www.oxfordbiomedica.co.uk/page.asp?pageid=59&newsid=114
37. Oxford Biomedica: Oxford BioMedica announces promising interim phase I/II results of ProSavin in Parkinson's disease. Press Release (2008): September 09. www.oxfordbiomedica.co.uk/page.asp?pageid=59&newsid=86
38. Oxford Biomedica: Oxford BioMedica announces six-month efficacy results with low dose of ProSavin in phase I/II trial in Parkinson's disease. Press Release (2008): November 19. www.oxfordbiomedica.co.uk/page.asp?pageid= 59&newsid=78
39. Oxford Biomedica: Oxford Biomedica announces update on phase I/II study of ProSavin in Parkinson's disease. Press Release (2009): July 13. www.oxfordbiomedica.co.uk/page.asp?pageid=59&newsid=236
40. Oxford Biomedica: Oxford BioMedica announces update on ProSavin phase I/II trial in Parkinson's disease and publication of preclinical results. Press Release (2009): October 15. www.oxfordbiomedica.co.uk/page.asp?pageid=59& newsid=246
41. Ceregene Inc: Ceregene announces clinical data from phase 2 clinical trial of CERE-120 for Parkinson's disease. Press Release (2008): November 26. www.ceregene.com/press-112608.asp
42. Ceregene Inc: Ceregene presents additional clinical data from phase 2 trial of CERE-120 for Parkinson's disease. Press Release (2009): May 27. www.ceregene.com/press-052709.asp
43. Herzog CD, Brown L, Gammon D, Kruegel B, Lin R, Wilson A, Bolton A, Printz M, Gasmi M, Bishop KM, Kordower JH et al: Expression, bioactivity, and safety 1 year after adenoassociated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support CERE-120 for Parkinson's disease. Neurosurgery (2009) 64 (4):602-613.
44. Eberling JL, Bankiewicz KS, Jordan S, VanBrocklin HF, Jagust WJ: PET studies of functional compensation in a primate model of Parkinson's disease. Neuroreport (1997) 8 (12):2727-2733.
45. Kells AP, Eberling J, Su X, Pivirotto P, Bringas J, Hadaczek P, Narrow WC, Bowers WJ, Federoff HJ, Forsayeth J, Bankiewicz KS: Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF. J Neurosci (2010) 30 (28):9567-9577. •• Presents data demonstrating that intraputamenal AAV2-GDNF infusions in chronic MPTP-induced parkinsonism in NHPs exhibit effective antergrade and retrograde transport of GDNF, despite marked nigrostriatal degeneration.
46. Eslamboli A, Georgievska B, Ridley RM, Baker HF, Muzyczka N, Burger C, Mandel RJ, Annett L, Kirik D: Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. J Neurosci (2005) 25 (4):769-777.
47. Eberling JL, Kells AP, Pivirotto P, Beyer J, Bringas J, Federoff HJ, Forsayeth J, Bankiewicz KS: Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys. Hum Gene Ther (2009) 20 (5):511-518.
48. Johnston LC, Eberling J, Pivirotto P, Hadaczek P, Federoff HJ, Forsayeth J, Bankiewicz KS: Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys. Hum Gene Ther (2009) 20 (5):497-510.
49. Su X, Kells AP, Huang EJ, Lee HS, Hadaczek P, Beyer J, Bringas J, Pivirotto P, Penticuff J, Eberling J, Federoff HJ et al: Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys. Hum Gene Ther (2009) 20 (12):1627-1640.
50. Manfredsson FP, Tumer N, Erdos B, Landa T, Broxson CS, Sullivan LF, Rising AC, Foust KD, Zhang Y, Muzyczka N, Gorbatyuk OS et al: Nigrostriatal rAAV-mediated DGNF overexpression induces robust weight loss in a rat model of age-related obesity. Mol Ther (2009) 17 (6):980-991. • Describes the direct effects of GDNF in inducing weight loss in rodents with intranigral injections of AAV-GDNF gene therapy.
51. Kirik D, Rosenblad C, Bjorklund A, Mandel RJ: Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: Intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci (2000) 20 (12):4686-4700. • Demonstrated that intrastriatal, but not intranigral, GDNF gene therapy is effective in restoring function in a rodent parkinsonian model.
52. Manfredsson FP, Burger C, Rising AC, Zuobi-Hasona K, Sullivan LF, Lewin AS, Huang J, Piercefield E, Muzyczka N, Mandel RJ: Tight long-term dynamic doxycycline responsive nigrostriatal GDNF using a single rAAV vector. Mol Ther (2009) 17 (11):1857-1867.
53. Recombinant DNA Advisory Committee (RAC), June 2009, Day 2: A phase I/II trial assessing the safety and efficacy of bilateral intraputaminal and intranigral administration of CERE-120 (adeno-associated virus serotype 2 [AAV2]-neurturin [NTN]) in subjects with idiopathic Parkinson's disease: NIH, Bethesda, MD, USA (2009). videocast.nih.gov/ram/rac061709.ram • The presentation of Ceregene to the RAC, proposing intrastriatal and intranigral AAV2-NTN gene therapy for PD.
54. Gossen M, Bujard H: Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA (1992) 89 (12):5547-5551.
55. Rivera VM, Clackson T, Natesan S, Pollock R, Amara JF, Keenan T, Magari SR, Phillips T, Courage NL, Cerasoli F Jr, Holt DA et al: A humanized system for pharmacologic control of gene expression. Nat Med (1996) 2 (9):1028-1032.
56. Sanftner LM, Rivera VM, Suzuki BM, Feng L, Berk L, Zhou S, Forsayeth JR, Clackson T, Cunningham J: Dimerizer regulation of AADC expression and behavioral response in AAV-transduced 6-OHDA lesioned rats. Mol Ther (2006) 13 (1):167-174.
57. Le Guiner C, Stieger K, Snyder RO, Rolling F, Moullier P: Immune responses to gene product of inducible promoters. Curr Gene Ther (2007) 7 (5):334-346. • Immunological reaction and functionality of regulated promoters in NHP peripheral tissues indicates that the RAPA system has advantages compared with the TET system.
58. Malagelada C, Jin ZH, Jackson-Lewis V, Przedborski S, Greene LA: Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease. J Neurosci (2010) 30 (3):1166-1175.
59. Cress DE: The need for regulatable vectors for gene therapy for Parkinson's disease. Exp Neurol (2008) 209 (1):30-33.
60. Kordower JH, Olanow CW: Regulateable promoters and gene therapy for Parkinson's disease: Is the only thing to fear, fear itself? Exp Neurol (2008) 209 (1):34-40.
61. Regulated GDNF vectors: Michael J Fox Foundation, New York, NY, USA (2009). www.pdonlineresearch.org/responses/10602/345/regulated-gdnf-vectors
62. Hadaczek P, Johnston L, Forsayeth J, Bankiewicz KS: Pharmacokinetics and bioactivity of glial cell line-derived factor (GDNF) and neurturin (NTN) infused in rat brain. Neuropharmacology (2010) 58 (7):1114-1121.
63. Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, Brooks DJ, Hotton G, Moro E, Heywood P, Brodsky MA et al: Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol (2006) 59 (3):459-466.
64. Hovland DN Jr, Boyd RB, Butt MT, Engelhardt JA, Moxness MS, Ma MH, Emery MG, Ernst NB, Reed RP, Zeller JR, Gash DM et al: Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuDGNF) in rhesus monkeys. Toxicol Pathol (2007) 35 (5):676-692.